Presented by: Sim Sui Theng Hospital Miri
Introduction Pathophysiology Microbial Etiology Clinical Manifestations Treatment Summary References
2
Sinusitis – An inflammation process involving the mucous membranes of the paranasal sinuses and/or underlying bone Normally involved the nasal mucosa rhinosinusitis Can be classified based upon duration of symptoms:
• Acute – sudden onset and lasts up to 4 weeks • Subacute – lasts between 4 – 12 weeks • Chronic – lasts at least 12 consecutive weeks
3
Fig Fig2: 1:Diagram Schematic of the drawing lateral showing nasal wall location and turbinates of the frontal, in relation ethmoid, to the frontal and maxillary and sphenoid sinuses sinuses and Eustachian tube orifice 4
Allergy, viral infections or air pollutants induce local inflammation in sinonasal mucosa Approximation of mucosal surfaces in the narrow channels of OMC* Swelling leads to impairment of mucociliary clearance & obstruction of the sinus ostia
*OMC- Osteomeatal complex
Sinus secretions pool & thicken, providing excellent culture medium for m/o
Sinusiti s
5
Acute Sinusitis
Chronic Sinusitis
-Well defined - Virus (most common), Bacteria (2%) - Examples of viruses: Rhinovirus, parainfluenza, influenza virus, RSV, adenovirus - Bacterial: • Community-acquired: Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis Staphyloccus aureus Anaerobic bacteria • Nosocomial: Staphylococcus aureus Streptococcal species Pseudomonas species Escherichia coli Klebsiella species Other Gram negative bacteria
-Not well defined - Normally involve polymicrobial infections - Anaerobes
6
Nasal congestion Purulent nasal discharge Maxillary tooth discomfort Facial pain/pressure (worse
bending forward) Headache Fever (Non-acute) Fatigue Cough Ear pain/ear fullness
when
Rhinosinusitis
7
(1)
Acute sinusitis
-
Viral rhinosinusitis Goal: Suppressing the full development of symptoms, especially the nasal fluid production that leads to nose blowing At the 1st sign of cold…
1st generation antihistamine (Eg. Chlorpheniramine) + NSAID (Eg. Ibuprofen) Administer q12H until cold symptoms clear
May add an oral decongestant (pseudoephedrine) and/or cough suppressant (dextromethorphan) as needed No improvement after 7-10 days? Antimicrobials may be required to treat secondary bacterial sinusitis
8
Community-acquired bacterial sinusitis Recommended antibiotics
Centers for Disease Control and Sinus and Allergy Health Partnership Prevention (CDC) Amoxycillin (1.5 to 3.5g/day)
Mild disease (No antibiotics in the last 4-6 weeks) -Amoxycillin-clavulanate (625mg bd) -Amoxycillin (1.5-3.5g/day) -Cefuroxime axetil (500mg bd) -Levofloxacin (500mg od) -Moxifloxacin (400mg od)
Doxycycline (100mg bd)
Mild disease (antibiotics in the last 4-6 weeks) OR Moderate disease (no antibiotics in this time frame): -Amoxycillin (3-3.5g/day) -Same as above (amoxycillin-clavulanate, cefuroxime, levofloxacin, moxifloxacin)
Trimethoprim-Sulfamethoxazole Moderate disease (antibiotics in the last 4-6 (1 tablet bd) weeks): -Amoxycillin-clavulanate, levofloxacin,
9
-
-
-
Nosocomial bacterial sinusitis Antimicrobial coverage should be directed at S. aureus and the Gram –ve bacteria based upon the sinus aspirate C&S test Fungal sinusitis Mainly involve the immunocompromised patients Surgical intervention – diagnostic biopsy and for debridement of the infection Empirical antifungal therapy: IV Amphotericin B 1mg/kg/day, duration depends on underlying host’s immune status extent of surgical debridement & response to therapy Chronic suppressive therapy following amphotericin B: oral itraconazole or voriconazole 10
(2)
Chronic sinusitis Antimicrobials: Amoxycillin-clavulanate (625mg bd) OR cefuroxime (500mg bd) for 21 days OR clarithromycin 500mg bd Decongestants: pseudoephedrine (short-term use); do not use topical nasal decongestant spray for chronic cases rebound rhinitis after 72H use Nasal irrigation: irrigate twice a day with warm saline solution using a bulb syringe Nasal steroids: 2 puffs of nasal spray/day (decrease mucosal inflammation and swelling, esp allergy) Adjunctive agents: Mucolytic agents (Eg. Guaifenesin); Antihistamines 11
Antihistamines
• MOA: Competes with histamines for H1-receptor sites on • • • •
effector cells in the gastrointestinal tract, blood vessels, and respiratory tract Side effects: drowsiness & sedative, dry mouth, constipation, urinary retention, nausea & vomiting and epigastric pain Newer antihistamines: less sedative Some patients may respond better with older antihistamines Counseling point:
Drowsiness, blurred vision, lightheadedness – avoid driving, handling machinery Consipation – take more liquids, regular exercise, fibercontaining diet Dry mouth – frequent mouth care Avoid alcohol, other antihistamines or mood stabilizers
12
Table 1: Relative Adverse Effect Profile of Antihistamines Medication
Relative Sedative Effect
Relative Anticholinergic Effect
Low Low Low
Moderate Moderate Moderate
High Moderate High
High High High
Low Moderate
Low to none Low to none
High
High
Low to moderate Low to none Low to none
Low to none Low to none Low to none
Alkylamine Class Brompheniramine maleate Chlorpheniramine maleate Dexchlorpheniramine maleate Ethanolamine Class Carbinoxamine maleate Clemastine fumarate Diphenhydramine HCl Ethylenediamine Class Pyrilamine maleate Tripelennamine HCl Phenothiazine Class Promethazine HCl “Non-sedating” Peripherally Selective Class Cetirizine Fexofenadine Loratadine
13
Decongestant
• MOA: Sympathomimetic agent which acts on
adrenergic receptors & produces vasoconstriction. It shrinks swollen mucosa & improve ventilation. • Topical decongestant: drops/spray • Problem: prolonged use can cause rebound vasodilation (rhinitis medicamentosa) ~ if use more than 3-5 days • Side effects: burning, stinging, sneezing & dryness of nasal mucosa • Counseling point: To use as small dose as infrequently as possible & only when absolutely necessary (Eg during bedtime to aid falling asleep); duration: limited to 3-5 days 14
Table 2: Duration of Action of Topical Decongestants Medication Duration (hr) Short Acting Phenylephrine HCl
Up to 4
Intermediate Acting Naphazoline HCl Tetrahydrozoline HCl
4–6
Long Acting Oxymetazoline HCl Xylometazoline HCl
Up to 12
15
Table 3: Oral Dosages of Commonly Prescribed Antihistamines and Decongestan Dosage and Interval Medication
Adults
Children
Antihistamines Chlorpheniramine maleate, plain
4mg q6H
6-12 yr: 2mg q6H 2-6 yr: 1mg q6H
Chlorpheniramine maleate, sustained release
8 – 12mg daily at bedtime or 8 – 12mg q8H
6-12 yr: 8mg at bedtime <6 yr: Not recommended
Diphenhydramine HCl
25 – 50mg q8H
5mg/kg/day q8H (up to 25mg per dose)
Clemastine fumarate
1.34mg bd to 2.68mg tds
Not recommended
Loratadine
10mg od
10mg od
Fexofenadine
60mg bd
6-11 yr: 30mg bd
Cetirizine
5 – 10mg od
>6 yr: 5mg od
60mg q4-6H 120mg q12H for SR tablet
6-12 yr: 30mg q4-6H 2-5 yr: 15mg q4-6H
25 – 50mg q4H
2-3 mg/kg/day divided q4H (up 16 to 25mg q4H)
Decongestants Pseudoephedrine Ephedrine sulfate
Nasal Steroid
• MOA: Reduce inflammatory by blocking mediator release,
suppress neutrophil chemotaxis, reduce intracellular edema & cause mild vasoconstriction • Eg: Budesonide nasal spray, beclomethasone dipropionate • Side effects: sneezing, stinging, headache, epistaxis • Should NOT be used in pts with nasal septum ulcers or recent nasal surgery or trauma • Counseling point: Blocked nose should be cleared with decongestant before administration to ensure adequate penetration Avoid sneezing/blowing their nose at least 10 mins after administration
17
Table 4: Dosage of Nasal Steroids Medication
Dosage and Interval
Beclomethasone dipropionate >12 yr: 1 inhalation (42µg) per nostril 2-4X/day (max: 336µg/day) 6-12 yr: 1 inhalation per nostril 3X/day Beclomethasone dipropionate, monohydrate
>12 yr: 1-2 inhalations once daily 6-12 yr: 1 inhalation per nostril bd
Budesonide
>6 yr: 2 sprays (64µg) per nostril a.m. & p.m., or 4 sprays per nostril a.m. (max: 256µg)
Fluticasone
Adults: 2 sprays (100µg) per nostril once daily; after a few days decrease to 1 spray per nostril Children >4 yr and adolescents: 1 spray per nostril od (max: 200µg/day)
Mometasone furoate
>12 yr: 2 sprays (100µg) per nostril od
18
19
1) 2)
3) 4) 5) 6)
Metson, R & Sindwani, R., 2007. Chronic sinusitis. UpToDate (15.2) Snow, V,et al. Ann Intern Med 2001; 134:495. Position paper endorsed by the American Academy of Family Physicians, the American College of Physicians-American Society of Internal Medicine, and the Infectious Diseases Society of America. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000; 123:S1 Gwaltney, JM, 2007. Acute sinusitis and rhinosinusitis in adults. UpToDate (15.1) Katzung, BG: Basic & Clinical Pharmacology Lexi-Comp-Drug Information Handbook International, 14th Edition
20